Literature DB >> 29524128

Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing.

Charlene Babra Waryah1, Colette Moses1,2, Mahira Arooj1,3, Pilar Blancafort4,5.   

Abstract

The completion of genome, epigenome, and transcriptome mapping in multiple cell types has created a demand for precision biomolecular tools that allow researchers to functionally manipulate DNA, reconfigure chromatin structure, and ultimately reshape gene expression patterns. Epigenetic editing tools provide the ability to interrogate the relationship between epigenetic modifications and gene expression. Importantly, this information can be exploited to reprogram cell fate for both basic research and therapeutic applications. Three different molecular platforms for epigenetic editing have been developed: zinc finger proteins (ZFs), transcription activator-like effectors (TALEs), and the system of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) proteins. These platforms serve as custom DNA-binding domains (DBDs), which are fused to epigenetic modifying domains to manipulate epigenetic marks at specific sites in the genome. The addition and/or removal of epigenetic modifications reconfigures local chromatin structure, with the potential to provoke long-lasting changes in gene transcription. Here we summarize the molecular structure and mechanism of action of ZF, TALE, and CRISPR platforms and describe their applications for the locus-specific manipulation of the epigenome. The advantages and disadvantages of each platform will be discussed with regard to genomic specificity, potency in regulating gene expression, and reprogramming cell phenotypes, as well as ease of design, construction, and delivery. Finally, we outline potential applications for these tools in molecular biology and biomedicine and identify possible barriers to their future clinical implementation.

Entities:  

Keywords:  CRISPR; Epigenome engineering; Genome editing; TALE; Zinc finger

Mesh:

Substances:

Year:  2018        PMID: 29524128     DOI: 10.1007/978-1-4939-7774-1_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

Review 1.  The role of environmental exposures and the epigenome in health and disease.

Authors:  Bambarendage P U Perera; Christopher Faulk; Laurie K Svoboda; Jaclyn M Goodrich; Dana C Dolinoy
Journal:  Environ Mol Mutagen       Date:  2019-06-20       Impact factor: 3.216

Review 2.  The past and presence of gene targeting: from chemicals and DNA via proteins to RNA.

Authors:  T M Geel; M H J Ruiters; R H Cool; L Halby; D C Voshart; L Andrade Ruiz; K E Niezen-Koning; P B Arimondo; M G Rots
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

Review 3.  Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.

Authors:  Mohammad Mijanur Rahman; Trygve O Tollefsbol
Journal:  Methods       Date:  2020-04-18       Impact factor: 3.608

Review 4.  Perspectives for epigenetic editing in crops.

Authors:  S Selma; D Orzáez
Journal:  Transgenic Res       Date:  2021-04-23       Impact factor: 2.788

Review 5.  Innovative Precision Gene-Editing Tools in Personalized Cancer Medicine.

Authors:  Xiaofeng Dai; Pilar Blancafort; Peiyu Wang; Agustin Sgro; Erik W Thompson; Kostya Ken Ostrikov
Journal:  Adv Sci (Weinh)       Date:  2020-04-23       Impact factor: 16.806

6.  Transcriptional repression of PTEN in neural cells using CRISPR/dCas9 epigenetic editing.

Authors:  C Moses; S I Hodgetts; F Nugent; G Ben-Ary; K K Park; P Blancafort; A R Harvey
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

Review 7.  Epigenetics, microRNA and Metabolic Syndrome: A Comprehensive Review.

Authors:  Farha Ramzan; Mark H Vickers; Richard F Mithen
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

Review 8.  Genome Editing Human Pluripotent Stem Cells to Model β-Cell Disease and Unmask Novel Genetic Modifiers.

Authors:  Matthew N George; Karla F Leavens; Paul Gadue
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-02       Impact factor: 6.055

Review 9.  Review of applications of CRISPR-Cas9 gene-editing technology in cancer research.

Authors:  Ziyi Zhao; Chenxi Li; Fei Tong; Jingkuang Deng; Guofu Huang; Yi Sang
Journal:  Biol Proced Online       Date:  2021-07-15       Impact factor: 3.244

Review 10.  Epigenetic Editing in Prostate Cancer: Challenges and Opportunities.

Authors:  Mariana Brütt Pacheco; Vânia Camilo; Rui Henrique; Carmen Jerónimo
Journal:  Epigenetics       Date:  2021-06-15       Impact factor: 4.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.